Market News & Trends
Galatea Bio Secures $25M to Develop Global Biobank & Enable Precision Health at Scale for All
Galatea Bio has secured $25 million in funding to drive discoveries in next-generation genetic analysis, biomarker discovery, and multi-omics disease modeling. Committed to enabling precision health…
NeOnc Technologies Expands Global Clinical Trial Network With CBCC Global Research to Accelerate Study of Brain Cancer Treatments
NeOnc Technologies Holdings, Inc. recently announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s…
CERo Therapeutics Holdings Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
CERo Therapeutics Holdings, Inc. recently announced that the company has received positive review from the US FDA on an amendment to its IND around Chemistry,…
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Polyrizon Ltd. recenytly announced the structuring of its clinical strategy for PL-14, the company’s proprietary intranasal allergy blocker for seasonal allergic rhinitis. The clinical strategy…
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles & Related Viruses
Decoy Therapeutics Inc. recently announced a series of antiviral drug candidates previously designed by its IMP3ACT™ platform to be broadly effective against viruses of the…
Acumen Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its ALTITUDE-AD Phase 2 trial of sabirnetug (ACU193) in patients with early Alzheimer’s disease. Acumen completed…
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug as a Monotherapy Treatment for Chronic Hepatitis D
Bluejay Therapeutics recently announced the first patient has been dosed in its AZURE-1 global pivotal clinical trial evaluating brelovitug (also known as BJT-778) for the…
Silo Pharma Achieves Key Milestone With First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Silo Pharma, Inc. recently announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset,…
Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology
Enable Injections, Inc. recently announced it has received its European Union Medical Device Regulation (EU MDR) CE Mark approval of the enFuse Syringe Transfer System. This…
Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
Researchers with Nanoscope Therapeutics Inc. recently announced the publication of a paper, A synthetic opsin restores vision in patients with severe retinal degeneration, in Molecular…
Porosome Therapeutics Unveils Groundbreaking Discovery in Alzheimer’s Disease Research & Treatment
Porosome Therapeutics, Inc. recently announced its latest development in identifying the secretory dysfunction responsible for Alzheimer’s Disease along with advancements in therapeutic neuronal nanomachines. These innovations…
First Patient Dosed in Immutep’s TACTI-004 Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the first patient has been successfully dosed in the Company’s pivotal TACTI-004 Phase 3 trial. TACTI-004 will evaluate Immutep’s eftilagimod alfa,…
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. recently announced dosing of new patients at Yale MS Center, which is participating in our multicenter Phase 2 clinical trial evaluating…
Character Biosciences Raises $93 Million to Advance Precision Medicine for Progressive Eye Diseases
Character Biosciences recently announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative…
IMUNON Finalizes Phase 3 Study Design With FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. recently announced the US FDA is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate…
Journey Medical Corporation Launches Emrosi (40-mg Minocycline Hydrochloride Modified-Release Capsules, 10-mg Immediate Release & 30- mg Extended Release) for the Treatment of Rosacea
Journey Medical Corporation recently announced the launch of and the first prescriptions filled for Emrosi (40-mg Minocycline Hydrochloride Modified-Release Capsules, 10-mg immediate release and 30-mg…
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function & Survival in MYBPC3 Cardiomyopathy Models
Tenaya Therapeutics, Inc. recently announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy…
Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form Category
Upperton Pharma Solutions is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO…
Traws Pharma’s Bird Flu Drug Candidate Presented at ICAR
Traws Pharma, Inc. recently announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment was presented yesterday in a…
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204
Silexion Therapeutics Corp. recently announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting…
